Johnson & Johnson to pay nearly ₹52,700 crore after lawsuits linked baby powder to ovarian cancer

Johnson & Johnson (JNJ) faces a significant financial settlement of approximately ₹52,700 crore (roughly $6.3 billion USD equivalent) stemming from accumulated talc-related litigation. This represents a material liability that compounds J&J's decades-long exposure to ovarian cancer claims, despite the company's consistent legal position that talc products are safe and properly marketed.

The settlement magnitude underscores mounting litigation risk that extends beyond individual jury verdicts into systemic financial drain. Despite J&J's defensive stance on product safety, the scale of this settlement suggests courts and plaintiff councils have achieved sufficient collective leverage to extract significant capital. This pattern of escalating settlements—even absent definitive scientific causation—creates balance-sheet pressure that investors must reconcile against the company's defensive messaging.

The talc litigation remains a key overhang for J&J's valuation multiple, particularly among risk-averse institutional investors. Health Care sector valuations depend partly on litigation tail-risk quantification; large settlements reduce forward earnings guidance predictability and elevate uncertainty premiums.

Sector implication: This case reinforces product-liability risk as a material drag on large-cap Health Care equities. The settlement does not resolve underlying scientific dispute but signals that financial resolution pathways continue regardless, potentially setting precedent for similar consumer health product challenges across the sector.